Top Glove Corp Bhd stock faces clouded earnings outlook amid rising costs and geopolitical risks

Analysts warn of volatile near-term performance for Top Glove Corp Bhd (ISIN: MYL7113OO003) due to surging raw material prices and Middle East tensions, despite recent profit gains. DACH investors eye supply chain exposure in this key glove maker.

Top Glove Corp Bhd, the world's largest rubber glove manufacturer, confronts a turbulent near-term landscape as analysts flag clouded earnings visibility from escalating raw material costs, currency swings, and geopolitical disruptions. Fresh research from March 20, 2026, highlights margin pressures persisting into Q3 ending May 31, with flat sales volumes expected amid Middle East uncertainties. For DACH investors, this Malaysian stock offers exposure to global healthcare supply chains but demands caution on cost pass-through and competition risks.

As of: 20.03.2026

By Elena Voss, Senior Healthcare Sector Analyst – 'Tracking Southeast Asian medtech firms like Top Glove amid global supply volatility and cost inflation.'

Recent Earnings Beat Expectations but Headwinds Mount

Top Glove Corp Bhd reported a second-quarter net profit of RM30.76 million for the period ended February 28, 2026, marking a 1.5% year-on-year increase. Revenue climbed 14% to RM1.01 billion, fueled by stronger orders from Europe and steady demand recovery. First-half net profit surged nearly 94% to RM69.34 million, underscoring operational improvements.

Yet, analysts temper optimism. CIMB Research notes near-term earnings may soften sequentially without one-off orders and due to input cost lags. The stock trades on Bursa Malaysia in MYR, reflecting these mixed signals in its healthcare sector peers.

Management guides for 5% quarter-on-quarter volume growth, supported by inventory restocking. However, NBR latex prices have doubled to US$1.50 per kg, prompting aggressive average selling price hikes to US$20 per 1,000 pieces for FY26-FY28.

Analyst Divergence on Target Prices and Ratings

Brokerages split on Top Glove's trajectory. CIMB maintains a 'hold' with a 63 sen target, citing bleak long-term prospects from oversupply and Chinese competition. TA Research reiterates 'sell' at 55 sen, trimming FY26 profit to RM156.7 million on supply disruptions and NBR inflation.

HLIB Research holds 'hold' at 54 sen, expecting flattish Q3 volumes amid Iran-related war uncertainties delaying distributor purchases. In contrast, MBSB Research stays 'buy' at 78 sen, praising production flexibility against 23-44% NBR spikes. Kenanga's 'outperform' at 75 sen factors 25-35% FY26 volume growth despite 12% earnings cuts.

Phillip Capital holds neutral at 54 sen, viewing Middle East risks as manageable via alternative routes. These revisions incorporate weaker USD/MYR at 3.85 and higher ASP assumptions.

Raw Material Surge and Pricing Power in Focus

Nitrile butadiene rubber (NBR) latex costs have nearly doubled, squeezing margins across the glove sector. Top Glove counters with significant ASP increases, but analysts question full pass-through to price-sensitive customers shifting to cheaper latex gloves. Operational flexibility, including production shifts, remains a key buffer.

The company assumes higher ASPs yet faces ringgit appreciation challenges. Global oversupply persists, with Chinese rivals intensifying pressure. For FY26-FY28, forecasts bake in these dynamics, balancing volume gains against cost inflation.

Sector peers like Hartalega and Supermax show similar volatility, with 7-day declines around 1-9% on Bursa Malaysia in MYR terms. Top Glove's market cap stands at roughly RM4.4 billion, positioning it as a leader amid recovery.

Geopolitical Tensions Disrupt Supply Chains

Middle East conflicts, including Iran war references, threaten logistics. Distributors delay buys, and shipments to the US face hurdles despite alternative routes. Management downplays major impacts, but Q3 volumes risk flatness.

Broader uncertainties include currency fluctuations, with USD/MYR weakening to 3.85 forecasts. These factors cloud earnings, prompting sequential softness warnings. Top Glove's global footprint aids resilience, but near-term volatility looms.

For investors, this underscores supply chain risks in essential medical goods. Demand recovery post-pandemic supports volumes, yet execution amid disruptions proves critical.

Relevance for DACH Investors

German-speaking investors in Germany, Austria, and Switzerland gain indirect exposure to resilient healthcare supply via Top Glove on Bursa Malaysia. Europe's strong Q2 orders highlight demand from DACH markets, where hygiene standards drive glove consumption. Portfolio diversification into Asian medtech counters Eurozone slowdowns.

ESG angles appeal: Top Glove's scale enables sustainable practices amid scrutiny. Currency hedging mitigates MYR exposure, while yield potential beats low European rates. Monitor Bursa Malaysia in MYR for entries, given analyst targets clustering 54-78 sen.

Key Risks and Long-Term Challenges

Persistent industry oversupply and Chinese competition erode pricing power. Elevated operating costs linger, with incomplete cost pass-through risking demand shifts. Geopolitical flare-ups amplify logistics woes.

Regulatory hurdles in key markets add uncertainty. While FY26 volume growth guides 25-35% year-on-year, execution hinges on cost management. Investors weigh balanced risk-reward, as challenges appear priced in.

Balance sheet strength supports navigation, but margin recovery pace decides outperformance. DACH portfolios should size positions conservatively amid volatility.

Strategic Outlook and Sector Context

Top Glove leverages scale for efficiency gains, targeting demand from restocking and emerging needs. Production flexibility offsets input spikes, positioning for recovery. Peers' mixed performances underscore selective opportunities.

Bursa Malaysia healthcare sector valuations hover at PE 20-40x, with Top Glove at elevated levels reflecting growth bets. Long-term, innovation in sustainable gloves could differentiate. For now, tactical plays suit volatility.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.